Fabry Disease - Pipeline Review, Q2 2011

Global Markets Direct, May 2011, Pages: 35

Fabry Disease - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Fabry Disease - Pipeline Review, Q2 2011', provides an overview of the Fabry Disease therapeutic pipeline. This report provides information on the therapeutic development for Fabry Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fabry Disease. 'Fabry Disease - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Fabry Disease.
- A review of the Fabry Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fabry Disease pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Fabry Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Fabry Disease pipeline depth and focus of Fabry Disease therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fabry Disease Overview
Therapeutics Development
An Overview of Pipeline Products for Fabry Disease
Fabry Disease Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Fabry Disease Therapeutics - Products under Development by Companies
Companies Involved in Fabry Disease Therapeutics Development
GlaxoSmithKline plc
Protalix BioTherapeutics, Inc.
Neuraltus Pharmaceuticals, Inc.
ISU ABXIS Co.,Ltd.
Fabry Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Amigal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRX-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JR-051 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NP003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amigal + Enzyme Replacement Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISU303 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fabry Disease Therapeutics – Drug Profile Updates
Fabry Disease - Featured News
Feb 16, 2011: Amicus Therapeutics Provides Positive Data Update From Phase II Long-Term Extension Study Of Amigal For Fabry Disease
Feb 09, 2011: Amicus Therapeutics Initiates Phase II Clinical Trial Evaluating Amigal Co-administered With Enzyme Replacement Therapy
Jan 19, 2011: Protalix Presents Data On Fabry Program With Experts In Field Of Lysosomal Disorders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Fabry Disease, Q2 2011
Products under Development for Fabry Disease – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
GlaxoSmithKline plc, 2011
Protalix BioTherapeutics, Inc., 2011
Neuraltus Pharmaceuticals, Inc., 2011
ISU ABXIS Co.,Ltd., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Fabry Disease Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Fabry Disease, Q2 2011
Products under Development for Fabry Disease – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Customers who bought this item also bought

• Nausea – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Essential Thrombocythemia – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Peanut Allergy – Pipeline Review, H1 2013